Splanchnic Vein Thrombosis in the Myeloproliferative Neoplasms
- 215 Downloads
Purpose of Review
To review the epidemiology, diagnostic challenges, pathogenesis, and treatment strategies for patients with myeloproliferative neoplasm-associated splanchnic vein thrombosis.
The epidemiology of myeloproliferative neoplasm-associated splanchnic vein thrombosis (MPN-SVT) has been well characterized. While typical MPN-associated thrombosis affects older patients and involves the arterial circulation, MPN-SVT mostly impacts younger women. An association with JAK2 V617F is well-known; recent studies have demonstrated only a weak association with CALR mutations. JAK inhibition may represent a novel treatment strategy, complementing anticoagulation, and management of portal hypertension.
While the epidemiology has been well characterized, more work is needed to identify novel contributors to disease pathogenesis, beyond the JAK2 V617F mutation itself, and endothelial compromise. Testing for MPN mutations in the setting of non-cirrhotic SVT is commonplace; JAK2 V617F is the most likely to be identified. Testing for CALR or MPL mutations requires clinical judgement, though not unreasonable. The mainstay of therapy is indefinite anticoagulation; the role of direct oral anticoagulants is unclear. JAK inhibition may play a role in addressing associated splenomegaly and portal hypertension.
KeywordsSplanchnic vein thrombosis JAK2 V617F mutation Myeloproliferative neoplasm Polycythemia vera
Compliance with Ethical Standards
Conflict of Interest
Brady Stein reports other from Incyte Corporation, outside the submitted work. Imo J. Akpan has no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 5.Gugliotta L, Iurlo A, Gugliotta G, Tieghi A, Specchia G, Gaidano G, et al. Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res. 2016;46:18–25. https://doi.org/10.1016/j.leukres.2016.04.004.CrossRefPubMedGoogle Scholar
- 6.Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544–51. https://doi.org/10.1182/blood-2013-11-539098.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.•• Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111–21. https://doi.org/10.1056/NEJMoa1701719. Large case control study shows that clonal hematopoiesis of indeterminate potential (CHIP) mutations such as DNMT3A , TET2 , ASXL1 , and JAK2 is associated with increased risk of coronary artery disease mediated by inflammation CrossRefPubMedGoogle Scholar
- 9.• Taniguchi Y, Tanaka H, Luis EJ, Sakai K, Kumode T, Sano K, et al. Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms. Int J Hematol. 2017;106(5):691–703. https://doi.org/10.1007/s12185-017-2302-5. Study shows that MPN patients with thrombotic events have higher plasma levels of procoagulant microparticle (MP) expressing tissue factor (TF) and suggests that MP expressing TF may potentially serve as another risk factor for thrombotic events in MPN in the future CrossRefPubMedGoogle Scholar
- 11.•• Ageno W, Riva N, Schulman S, Beyer-Westendorf J, Bang SM, Senzolo M, et al. Long-term clinical outcomes of splanchnic vein thrombosis: results of an international registry. JAMA Intern Med. 2015;175(9):1474–80. https://doi.org/10.1001/jamainternmed.2015.3184. Large prospective study of 604 consecutive patients with SVT which shows that these patients have an increased long-term risk of recurrent thrombosis. That risk is even higher in patients with solid cancer, myeloproliferative neoplasms, and unprovoked SVT CrossRefPubMedGoogle Scholar
- 16.•• Hultcrantz M, Bjorkholm M, Dickman PW, Landgren O, Derolf AR, Kristinsson SY, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med. 2018;168:317–25. https://doi.org/10.7326/M17-0028. Large study in Sweden of 9429 patients with MPNs and 35,820 matched control shows that patients with MPN have a higher rate of thrombosis compared to the control participants across all age groups. The thrombotic rate is much higher shortly after diagnosis. This study includes the hazard ratios for both arterial and venous thrombosis.CrossRefPubMedGoogle Scholar
- 17.Yan M, Geyer H, Mesa R, Atallah E, Callum J, Bartoszko J, et al. Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension. Clin Lymphoma Myeloma Leuk. 2015;15(1):e1–5. https://doi.org/10.1016/j.clml.2014.04.004.CrossRefPubMedGoogle Scholar
- 19.Karakose S, Oruc N, Zengin M, Akarca US, Ersoz G. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis. Turk J Gastroenterol. 2015;26(1):42–8. https://doi.org/10.5152/tjg.2015.5738.CrossRefPubMedGoogle Scholar
- 24.• Poisson J, Plessier A, Kiladjian JJ, Turon F, Cassinat B, Andreoli A, et al. Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: a prospective cohort study. J Hepatol. 2017;67(3):501–7. https://doi.org/10.1016/j.jhep.2017.04.021. The study shows that calreticulin mutations are rare in patients with SVT CrossRefPubMedGoogle Scholar
- 26.Rosti V, Bonetti E, Bergamaschi G, Campanelli R, Guglielmelli P, Maestri M, et al. High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis. PLoS One. 2010;5(12):e15277. https://doi.org/10.1371/journal.pone.0015277.CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Villani L, Bergamaschi G, Primignani M, Rosti V, Carolei A, Poletto V, et al. JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms. Leuk Res. 2012;36(1):e7–9. https://doi.org/10.1016/j.leukres.2011.08.008.CrossRefPubMedGoogle Scholar
- 30.Gianelli U, Iurlo A, Cattaneo D, Bossi A, Cortinovis I, Augello C, et al. Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis. Leuk Res. 2015;39(5):525–9. https://doi.org/10.1016/j.leukres.2015.03.009.CrossRefPubMedGoogle Scholar
- 31.•• De Stefano V, Vannucchi AM, Ruggeri M, Cervantes F, Alvarez-Larran A, Iurlo A, et al. Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. Blood Cancer J. 2016;6(11):e493. https://doi.org/10.1038/bcj.2016.103. Large retrsopective study of MPN-SVT shows a lower recurrence of thrombosis in anticoagulated patients. Higher recurrence was associated with BCS, splenomegaly, and leukocytosis CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Riva N, Ageno W, Poli D, Testa S, Rupoli S, Santoro R, et al. Recurrent thrombotic events after discontinuation of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter retrospective cohort study. Gastroenterol Res Pract. 2015;2015:620217. https://doi.org/10.1155/2015/620217.CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Kreher S, Ochsenreither S, Trappe RU, Pabinger I, Bergmann F, Petrides PE, et al. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (OGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.). Ann Hematol. 2014;93(12):1953–63. https://doi.org/10.1007/s00277-014-2224-8.CrossRefPubMedGoogle Scholar
- 38.Spaander MC, Hoekstra J, Hansen BE, Van Buuren HR, Leebeek FW, Janssen HL. Anticoagulant therapy in patients with non-cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding. J Thromb Haemost. 2013;11(3):452–9. https://doi.org/10.1111/jth.12121.CrossRefPubMedGoogle Scholar
- 39.• Potthoff A, Attia D, Pischke S, Mederacke I, Beutel G, Rifai K, et al. Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms. Liver Int. 2015;35(8):2042–9. https://doi.org/10.1111/liv.12816. Retrospective study of long-term outcomes of patients who received liver transplant for Budd-Chiari due to MPN showed that there was no difference in outcomes in MPN patients compared to those without MPN. This study highlights that MPN patients are able to undergo liver transplant if needed and that liver transplant does not hasten the natural course of MPN CrossRefPubMedGoogle Scholar
- 42.•• Reilly CR, Babushok DV, Martin K, Spivak JL, Streiff M, Bahirwani R, et al. Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension. Am J Hematol. 2017;92(9):909–14. https://doi.org/10.1002/ajh.24798. Multicenter retrospective analysis of patients with MPN-associated portal hypertension who received TIPs intervention shows that TIPS is an effective treatment in this entity CrossRefPubMedGoogle Scholar
- 44.•• Pieri L, Paoli C, Arena U, Marra F, Mori F, Zucchini M, et al. Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. Am J Hematol. 2017;92(2):187–95. https://doi.org/10.1002/ajh.24614. Phase 2 clinical trial that shows ruxolitnib is safe in patients with MPN-SVT and it also reduces spleen size and spleen stiffness. Decrease in spleen /liver stiffness is typically associated with improved pHTN in patients with cirrhosis CrossRefPubMedGoogle Scholar